In addition to malignant cells, the tumor microenvironment also includes nonmalignant cells, secreted proteins, and blood vessels that surround and support the growth of the tumor. Interactions between the various components of the tumor microenvironment are significant; tumor cells can change the nature of the microenvironment, and conversely, the microenvironment can affect how a tumor grows and spreads. The structure and composition of the tumor microenvironment varies among different types of cancers and between patients. This paper focuses on the composition and function of the tumor microenvironment in hematologic malignancies with a specific focus on B-cell lymphomas.
INTRATUMORAL T CELLS
Tumor biopsies from patients diagnosed with B-cell lymphomas are typically characterized by a high prevalence of T cells within the tumor microenvironment, with T cells comprising up to 50% of the intratumoral cells. These intratumoral T cells have a signifıcant effect on antitumor immunity, and the frequency and location of these cells are predictive of patient outcome. 1 As T cells are generally heterogeneous, the prevalence of various T-cell populations within the microenvironment may influence tumor immunity in both positive and negative ways. In patients with lymphoma, a high frequency of intratumoral T cells is generally associated with a favorable prognosis. [2] [3] [4] However, other studies have reported that the presence of only certain subsets of T cells are predictive of patient outcome. 5, 6 
CD8؉ T Cells
For the most part, T lymphocytes can be divided into two groups: those expressing CD4 and those expressing CD8. In general, CD4ϩ T cells help other immune cells, while CD8ϩ
T cells are generally thought to induce apoptosis of target cells through the secretion of perforin and granzyme B. In biopsy specimens from patients with follicular lymphoma (FL), the frequency of intratumoral CD8ϩ T cells varies, ranging from 10% to 50%. 7 Unlike CD4ϩ cells that have been detected both within and outside the malignant follicles, CD8ϩ cells are mainly perifollicular. Although it has been speculated that these perifollicular CD8ϩ cells are involved in protecting the follicle, data from three-dimensional confocal laser scanning microscopy studies suggest that most of the CD8ϩ granzyme Bϩ cells appear to target FL B cells, as there was physical contact between cytotoxic CD8ϩ T lymphocytes and malignant B cells. 8 Further evidence that CD8ϩ T cells target lymphoma cells has come from in vitro studies, whereby CD8ϩ T-cell clones demonstrated specifıc cytotoxicity directed against autologous lymphoma cells. [9] [10] [11] In clinical studies, higher intratumoral CD8ϩ T-cell numbers are associated with longer overall survival as well as disease-specifıc survival, independent of other prognostic factors. 7, 8 Collectively, these fındings suggest that intratumoral CD8ϩ T cells are part of a lymphoma-specifıc immune response.
CD4؉ T Cells
CD4ϩ T cells are key regulators of the immune response, enhancing the production of antibodies by neighboring B cells, stimulating antimicrobial activity by macrophages, recruiting neutrophils, eosinophils, and basophils to sites of inflammation, and promoting an effective immune response through the production of cytokines and chemokines. After initial studies indicated that some CD4ϩ cells produce interferon-gamma (IFN-␥) and others produce interleukin-4 (IL-4), it has been recognized that CD4ϩ T cells are not a single subset of immune cells but instead, represent a series of cell populations with distinct biologic functions. 12 T reg cells. Regulatory T (T reg ) cells play a pivotal role in malignancy by limiting immune activation and specifıc immune responses. T reg cells have been further characterized as CD4ϩ/CD25ϩ T cells. 13 These "naturally occurring" T reg cells make up but a small subset of CD4ϩ T cells, representing approximately 5% to 10% of peripheral CD4ϩ T cells in both mice and humans. Yet T reg cells can also be generated by antigenic stimulation, and these cells are defıned as "inducible " T reg cells. The forkhead/winged helix transcription factor family member p3 (FOXP3) is a master transcriptional regulator of the development and function of T reg cells, and FOXP3 is now used as a specifıc marker for both naturally occurring and inducible T reg cells. [14] [15] [16] T reg cells were originally recognized to suppress effector T cells. However, subsequent studies have reported that T reg cells suppress other types of immune cells as well, including B cells and natural killer (NK) cells. Because of this, T reg cells are capable of influencing a variety of immune responses, including autoimmune, antimicrobial, and antitumor immunity.
Elevated numbers of T reg cells are usually detected in peripheral blood and biopsy specimens obtained from patients with cancer. In lymphoma biopsy specimens, T reg cells are highly prevalent and have been found to effıciently suppress antitumor immunity through the suppression of other intratumoral CD4ϩ and CD8ϩ T-cell populations. [17] [18] [19] The mechanisms underlying the elevated number of T reg cells in B-cell lymphoma include increased recruitment as well as de novo generation of T reg cells. Chemokine receptor 4 (CCR4) and chemokine ligand 22 (CCL22) have also been observed to play crucial roles in attracting T reg cells to the tumor site. 17 In addition, de novo generation of T reg cells is an important mechanism of immunosuppression in lymphoma. [20] [21] [22] Tumor growth factor-beta (TGF-␤) derived from lymphoma cells has been found to induce FOXP3 expression, leading to the subsequent conversion of CD4ϩ/CD25-T cells to T reg cells. 23 Interactions between CD27 and CD70 appear to be responsible for the generation of T reg cells by lymphoma B cells, as CD70-expressing lymphoma B cells effıciently induce FOXP3 expression in intratumoral CD4ϩ/CD25-T cells. 20 Clinically, T reg cells have signifıcant prognostic relevance in lymphoma. Initial studies reported that low numbers of T reg cells are associated with refractory disease, transformation, and a more aggressive histology, whereas high numbers of intratumoral T reg cells were predictive of improved survival in FL. 5, 24 However, these results were not reproducible, and subsequent studies noted that the number of infıltrating FOXP3 cells did not correlate with overall survival. 25, 26 This discrepancy may be caused by differences in the therapeutic regimens administered to patients in the individual studies or also the distribution pattern of FOXP3ϩ T reg cells. 26 Patients with FOXP3ϩ cells present in a follicular pattern displayed an elevated risk of transformation and a shorter overall survival than patients with a more diffuse distribution of FOXP3ϩ cells. 3 Taken together, these fındings suggest that the location of T reg cells in the tumor microenvironment and their effect on other intratumoral immune cells have an important effect on outcome for patients with lymphoma.
T H 1 and T H 2 cells.
Initially, CD4ϩ T cells were defıned as helper cells (T H ) to distinguish them from their cytotoxic counterpart, CD8ϩ T cells. T H cells were further subgrouped into T H 1 and T H 2 cells based on their cytokine-secreting profıles. 12 The recent identifıcation of master transcriptional regulators for various T-cell subtypes has further divided the T H family into four major lineages: T H 1, T H 2, T H 17, and T FH cells. [27] [28] [29] As mentioned previously, CD4ϩ/CD25ϩ T reg cells form the other major lineage of CD4ϩ T cells. 30 Investigations into the roles of the T H 1 and T H 2 immune responses in various human diseases suggest that the balance between the two cell types is often critically skewed. For example, immune responses in acute bacterial infection such as tuberculosis are often predominantly of the T H 1 type, whereas the inflammation seen in allergic conditions such as asthma is commonly mediated by T H 2 type immunity. However, skewing between a T H 1 and T H 2 phenotype has not been defınitively proven in B-cell malignancies. Jones et al investigated 44 patients with B-cell NHL, and found mRNA levels of both T H 1 and T H 2 cytokines to be expressed at high levels as measured by reverse transcription polymerase chain reaction. 31 Although the T H 1 immune response is typically thought to be more effective than T H 2 in promoting antitumor immunity and the T H 2 immune response may actually support tumor growth by both promoting angiogenesis and inhibiting T H 1 immune response, this study indicated that high levels of IL-4 (consistent with a T H 2 response) correlated with longer survival times. In contrast, Ansell et al have found that elevated levels of serum IL-12-the major cytokine involved in T H 1 immunity-are associated with a poorer prognosis in FL. 32 These fındings challenge the tradi- 
Factors Regulating T-Cell Function
Many mechanisms are involved in regulating T-cell function including the activation of suppressive signaling pathways by costimulatory molecules. One such set of signals is mediated via interactions between PD-1 and PD-L1. PD-1-a member of the CD28/CTLA-4 family-is induced in activated T cells. On interacting with its ligands, PD-L1 and PD-L2, PD-1 negatively regulates T-cell receptor (TCR) signaling and decreases proliferation and cytokine production in T cells. Yang et al detected high levels of PD-1 on intratumoral CD4ϩ/CD25-T cells, whereas CD4ϩ/CD2ϩ T reg cells express PD-L1 on TCR activation. 17 This expression pattern indicated a role for PD-1 and PD-L1 interactions in intratumoral T reg cell-mediated immune suppression. In fact, blocking the interaction between PD-1 and PD-L1 with a neutralizing antibody attenuated T reg cell-mediated inhibition of CD4ϩ/CD25-T cells. A study of 100 FL biopsy specimens confırmed the expression of PD-1 on T cells and also found that PD-1 expression was rarely detected on FOXP3ϩ T reg cells. 6 TIM-3-a family member of the T-cell immunoglobulin and mucin domain proteins-is known to inhibit T H 1-mediated auto-and alloimmune responses and to promote immunologic tolerance. 37, 38 Increasing evidence suggests that instead of functioning as an inhibitor of T H 1 cells, TIM-3 actually plays a crucial role in mediating T-cell exhaustion and contributes to negative immune responses in both viral infections and tumors. 39, 40 TIM-3-expressing T cells are frequently detected in biopsy specimens of patients with FL and display exhausted phenotypic and functional characteristics. 32 Intratumoral TIM-3ϩ T cells also express PD-1 and have impaired function. Of note, PD-1 high CD4ϩ T cells in FL biopsies have demonstrated coexpression of CXCR5 and have been characterized as T FH cells, indicating that TIM-3 may be a more specifıc marker of exhausted T cells than PD-1. Importantly, the numbers of CD4ϩ/TIM-3ϩ T cells have been associated with poor survival in patients with FL. IL-12 plays a key role in upregulating TIM-3 expression, inducing T-cell exhaustion and contributing to the high number of TIM-3ϩ T cells in FL. 32 In contrast to TIM-3 expression, the prognostic signifı-cance of PD-1 expression remains controversial. Initial data suggested that the number of PD-1ϩ cells is lower in patients with a poor performance status and high serum lactate dehydrogenase (LDH), whereas a high frequency of PD-1ϩ T cells is associated with an increased overall survival in patients with FL. 6, 41 However, subsequent studies have identifıed PD-1ϩ T cells to be independent prognostic risk factors for decreased overall survival in FL. 42 These disparate fındings may be caused by differences among the study populations, patient selection criteria or clinical management as well as the varying methodologies used to detect and quantify PD-1ϩ T cells. The fınding that PD-1ϩ T cells are heterogeneous cells with phenotypes of both T FH and exhausted T cells may also contribute to the inconsistent observations.
INTRATUMORAL MONOCYTES AND MACROPHAGES

Tumor-Associated Macrophages
Cells of the monocyte lineage are categorized based on maturation status, and their progeny include macrophages and dendritic cells. Differentiation of these cells is defıned by a variety of cell surface markers such as CD11c, CD14, and CD68. Monocytic cells are essential to the innate immune response, serving as a fırst line of resistance against pathogens while also activating adaptive immune responses. Depending on the type of stimulation, macrophages may undergo classical M1 activation (stimulated by lipopolysaccharide and IFN-␥) or, alternatively, M2 activation (stimulated by IL-4 and IL-13). The resulting M1 and M2 macrophages produce distinct cytokines and have different functional roles in the innate immune response. For example, M1 macrophages secrete IL-12 and promote T H 1 cell development, whereas M2 macrophages produce IL-10 and facilitate the development of T H 2 cells. 43 M1 macrophages are recruited to early-stage tumors, infıltrating the tumor microenvironment in response to inflammatory signals. Subsequently, M1 macrophages then release proinflammatory cytokines and chemokines to promote the development and differentiation of T and NK cells. In later stages, macrophages differentiate into a subpopulation called tumorassociated macrophages (TAMs). TAMs may polarize to M2 cells, releasing cytokines to encourage T H 2 differentiation and recruitment. Furthermore, TAMs inhibit antitumor immunity by secreting suppressive cytokines, such as TGF-␤, leading to an increase in angiogenesis and the expression of growth factors involved in supporting tumor growth. Clinical observations suggest that an increase in the number or density of intratumoral macrophages correlates with both progression and prognosis in the majority of malignancies, including B-cell NHL and Hodgkin lymphoma. 44 Farinha et al conducted a study in patients with FL to examine the predictive value of multiple biomarkers on outcome, focusing specifıcally on macrophages. 45 Using tissue microarrays, CD68 was the only biomarker that correlated with overall survival. An increase in the number of CD68-expressing cells-termed lymphoma-associated macrophages (LAM)-was associated with diminished survival. This fınding confırmed the results of a previous gene-profıling study in FL, which found a macrophage-related immune signature to be highly correlated with a poorer prognosis. 1 Other studies have confırmed that CD68ϩ LAM are associated with an inferior outcome but have also demonstrated that a therapeutic regimen that includes the anti-CD20 antibody rituximab can circumvent this association. 46 
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) comprise a heterogeneous population of immature myeloid cells that have not yet undergone differentiation into macrophages, dendritic cells, or granulocytes and normally exist in the bone marrow of healthy individuals. MDSCs are generally divided into two distinct subsets: monocytic and granulocytic. MDSCs are easily characterized in mice using CD11b and Gr-1. However, the phenotypes used to defıne this cell population in humans varies signifıcantly in different tissues, making it diffıcult to quantify MDSCs in patients. 47, 48 Various studies have suggested that MDSCs are highly prevalent in a variety of cancers and suppress NK and T cells either through direct cell contact, cytokine-mediated cross-talk or byproducts of metabolic pathways. MDSCs also have been identifıed as regulators of T reg cell expansion and activation while also supporting tumor angiogenesis and metastasis.
MDSCs have been extensively studied in solid tumors, but little is known about their role in hematologic malignancies. Recently, Lin et al identifıed a CD14ϩ subpopulation with low or absent HLA-DR expression in the peripheral blood of patients with B-cell NHL. 49 These CD14ϩDR low/-monocytes inhibited T-cell function through a mechanism involving the metabolism of arginine. A high prevalence of this suppressive monocytic subpopulation correlated with both disease progression and overall survival. Studies in multiple myeloma and T-cell lymphoma have confırmed these fındings and highlight the role of HLA-DR expression in defıning MDSCs in hematologic malignancies. 50, 51 Because MDSCs are immature monocytic or granulocytic cells with immunosuppressive properties, promoting their differentiation into mature macrophages or dendritic cells may be a clinically useful strategy to decrease the number of MDSCs. Two different agents have proven useful in this endeavor: 25-hydroxyvitamin D3 (VD3) and all-trans-retinoic acid (ATRA). Therapeutic administration of either VD3 or ATRA to patients with cancer has been associated with a decrease in MDSCs and increased numbers of mature HLA-DRϩ monocytes. 52, 53 
OTHER INTRATUMORAL CELLS NK Cells
NK cells are a type of cytotoxic lymphocyte-critical to innate immunity-that do not require recognition of the major histocompatibility complex (MHC) presented on infected cell surfaces. NK cells are composed of two subsets: less mature CD3-/CD56 bright and more mature CD3-/CD56 dim cells as defıned by both functional and phenotypic characteristics. 54 CD56 bright cells are mainly present in lymph nodes, express dim or negative CD16 and produce abundant cytokines such tumor necrosis factor-alpha (TNF-␣) and IFN-␥. In contrast, CD56 dim cells are typically detected in peripheral blood, strongly express CD16, and have a cytotoxic function. The majority of studies on the tumor microenvironment have focused on the role of intratumoral T cells and macrophages, and few studies have examined the function of NK cells in B-cell NHL. Gibson et al analyzed the total number of NK cells, as well as NK subsets, and correlated these values with disease progression in B-cell NHL. 55 The proportions of NK cells did not differ when stratifıed by Ann Arbor stage. However, the total number of NK cells varied signifıcantly depending on the tissue site sampled, and the proportions of NK cells did correlate with the Follicular Lymphoma International Prognostic Index score. Data obtained from patients with other B-cell lymphomas indicate that higher proportions of NK cells in the peripheral blood are associated with a favorable prognosis. 56, 57 
Follicular Dendritic Cells
Follicular dendritic cells (FDCs) are stromal cells located within the GC of lymphoid follicles and comprise 1% of all GC cells. 58 Fully differentiated FDCs express low-affınity immunoglobulin E receptor CD23, complement receptors CD21 and CD35 and lymphocyte chemoattractant CXCL13. Although other antigen (Ag)-presenting cells internalize, process, and present Ag, FDCs present intact Ag-antibody (Ab) complexes on their cell surface. Binding to these Ag-Ab complexes is associated with survival and differentiation of B cells into memory B cells or plasma cells. In vitro studies using FDCs cell lines have demonstrated that FDCs preferentially bind and provide survival signals to GC B cells, whereas the majority of unbound B cells undergo apoptosis. 59 CD40L and cytokines such as IL-15 are critically involved in FDCmediated proliferation and survival of GC B cells. 59 In patients with FL, FDCs may be immature and have either low levels or negative expression of surface markers such as CD23, CD21, or CD35. [60] [61] Patients who have FL with mature FDCs in the lymph nodes have increased numbers of FL-associated T cells and are more likely to be diagnosed at a higher stage. 60 Conversely, Cui reported that atypical immature FDCs, which have diminished or absent CD21 staining, are present in 11% of patients with FL, and a higher predominance of mature FDCs in the tumor was associated with advanced clinical stage (III or IV) than cases demonstrating an atypical immature FDC network. 62 
CONCLUSION
Hematologic malignancies are characterized by a more unique tumor microenvironment than solid tumors, and the presence of a substantial numbers of intratumoral immune cells influence both antitumor immunity and patient survival. Immune cells, including T cells and macrophages, can reside within follicles and have direct contact with neighboring malignant B cells. In return, lymphoma B cells can themselves manipulate the microenvironment by skewing the differentiation of immune cells, attracting regulatory T cells or suppressive monocytes, or secreting immunosuppressive cytokines. All of these mechanisms promote immune suppression, immune exhaustion, and immune dysfunction within sites involved by lymphoma, making the targeting and killing of malignant cells by tumor-specifıc effector cells very diffıcult. Therefore, therapies that promote an effective antitumor response while reversing immunosuppression and dysfunction may prove to be the most effective in the treatment of patients with hematologic malignancies. It is striking that this theme of tumor microenvironmental immune suppression has also emerged in the analysis of solid tumors, especially invasive carcinomas. 63 For example, in pancreatic ductal adenocarcinoma, an immunosuppressive host response including T reg cells, MDSC, M1 macrophages, and immunosuppressive cytokines is also prominent pathophysiological feature-as it is in hematologic malignancies-and suggests novel therapeutic targets. 64 It seems likely that lessons learned from independent analyses of hematologic malignancies and solid tumors with regard to the tumor microenvironment are, to a large extent, globally applicable.
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